Publication Name	World Journal of Clinical Cases
Manuscript ID	94375
Country	United Kingdom

Received	2024-03-18 00:59
Peer-Review Started	2024-03-18 00:59
To Make the First Decision
Return for Revision	2024-04-19 21:07
Revised	2024-04-20 22:12
Second Decision	2024-05-17 02:47
Accepted by Journal Editor-in-Chief
Accepted by Executive Editor-in-Chief	2024-05-17 09:13
Articles in Press	2024-05-17 09:13
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript	2024-07-03 04:33
Publish the Manuscript Online	2024-07-11 09:22

ISSN	2307-8960 (online)
Open Access	This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Copyright	The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Gastroenterology & Hepatology
Manuscript Type	Editorial
Article Title	Navigating treatment resistance: Janus kinase inhibitors for ulcerative colitis
Manuscript Source	Invited Manuscript
All Author List	Jonathan Soldera
ORCID	Author(s) ORCID Number Jonathan Soldera http://orcid.org/0000-0001-6055-4783
Funding Agency and Grant Number
Corresponding Author	Jonathan Soldera, MD, MSc, PhD, Executive Associate Editor-in-Chief, Instructor, Acute Medicine and Gastroenterology, University of South Wales, Llantwit Road, Cardiff CF37 1DL, United Kingdom. jonathansoldera@gmail.com
Key Words	Inflammatory bowel disease; Ulcerative colitis; Janus kinase inhibitor; Upadacitinib; Tofacitinib; Infliximab
Core Tip	This editorial explores the efficacy and safety of Janus kinase inhibitors, specifically upadacitinib and tofacitinib, in refractory ulcerative colitis (UC) and acute severe UC (ASUC). Highlighting a compelling case report, it underscores the potential of these small-molecule therapies, either alone or in combination with biologics, to achieve and maintain disease remission. Furthermore, it emphasizes the importance of considering overlapping infections in ASUC and the need for prompt recognition by colorectal surgeons. This editorial advocates for further research to refine treatment strategies for patients with treatment-resistant UC, shedding light on promising therapeutic approaches.
Publish Date	2024-07-11 09:22
Citation	<p>Soldera J. Navigating treatment resistance: Janus kinase inhibitors for ulcerative colitis. <i>World J Clin Cases</i> 2024; 12(24): 5468-5472</p>
URL	https://www.wjgnet.com/2307-8960/full/v12/i24/5468.htm
DOI	https://dx.doi.org/10.12998/wjcc.v12.i24.5468

Full Article (PDF)	WJCC-12-5468-with-cover.pdf
Manuscript File	94375_Auto_Edited-JLW.docx
Answering Reviewers	94375-answering-reviewers.pdf
Audio Core Tip	94375-audio.ogg
Conflict-of-Interest Disclosure Form	94375-conflict-of-interest-statement.pdf
Copyright License Agreement	94375-copyright-assignment.pdf
Non-Native Speakers of English Editing Certificate	94375-non-native-speakers.pdf
Peer-review Report	94375-peer-reviews.pdf
Scientific Misconduct Check	94375-scientific-misconduct-check.png
Scientific Editor Work List	94375-scientific-editor-work-list.pdf
CrossCheck Report	94375-crosscheck-report.pdf